BR0010683A - Formas polimórficas de um agente antidiabético: processo para seu preparo e composições farmacêuticas contendo o mesmo - Google Patents

Formas polimórficas de um agente antidiabético: processo para seu preparo e composições farmacêuticas contendo o mesmo

Info

Publication number
BR0010683A
BR0010683A BR0010683-6A BR0010683A BR0010683A BR 0010683 A BR0010683 A BR 0010683A BR 0010683 A BR0010683 A BR 0010683A BR 0010683 A BR0010683 A BR 0010683A
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
polymorphic forms
same
Prior art date
Application number
BR0010683-6A
Other languages
English (en)
Inventor
Om Reddy Gaddam
Rajender Kumar Potlapally
Raju Sirisilla
Vyas Krishnamurthi
Sreenivasa Rao Dharmaraja
Ramabhadra Sarma Mamillapalli
Original Assignee
Reddy Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1999/000681 external-priority patent/WO2000063191A1/en
Application filed by Reddy Research Foundation filed Critical Reddy Research Foundation
Publication of BR0010683A publication Critical patent/BR0010683A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

"FORMAS POLIMóRFICAS DE UM AGENTE ANTIDIABéTICO: PROCESSO PARA SEU PREPARO E COMPOSIçõES FARMACêUTICAS CONTENDO O MESMO". A presente invenção refere-se a novas formas polimórficas/pseudopolimórficas de sal de arginina de ácido 3-[4-[2-(fenoxazin-10-il)etóxi]fenil]-2-etoxipropanóico, tendo a fórmula (I). A invenção também retere-se a uma composição farmacêutica compreendendo a nova forma polimórfica ou sua mistura e um veículo farmaceuticamente aceitável. As formas polimórficas da presente invenção são mais ativas, como agente antidiabético e hipolipidêmico, do que o novo ácido 3-[4-[2-(fenoxazin-10-il)etóxi]fenil]-2-etoxipropanóico.
BR0010683-6A 1999-04-16 2000-04-17 Formas polimórficas de um agente antidiabético: processo para seu preparo e composições farmacêuticas contendo o mesmo BR0010683A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB1999/000681 WO2000063191A1 (en) 1999-04-16 1999-04-16 Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
IN436MA1999 1999-04-19
PCT/IB2000/000470 WO2000063192A1 (en) 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
BR0010683A true BR0010683A (pt) 2003-07-01

Family

ID=26318745

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010683-6A BR0010683A (pt) 1999-04-16 2000-04-17 Formas polimórficas de um agente antidiabético: processo para seu preparo e composições farmacêuticas contendo o mesmo

Country Status (17)

Country Link
EP (1) EP1171430A1 (pt)
CN (1) CN1351597A (pt)
AU (1) AU3831300A (pt)
BG (1) BG106022A (pt)
BR (1) BR0010683A (pt)
CA (1) CA2370401A1 (pt)
CZ (1) CZ20013711A3 (pt)
EE (1) EE200100529A (pt)
HR (1) HRP20010748A2 (pt)
HU (1) HUP0200758A3 (pt)
IL (1) IL145958A0 (pt)
MX (1) MXPA01010472A (pt)
NO (1) NO20015016L (pt)
PL (1) PL351492A1 (pt)
RU (1) RU2001130883A (pt)
TR (1) TR200103851T2 (pt)
WO (1) WO2000063192A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60114996T2 (de) 2000-03-08 2006-08-10 Novo Nordisk A/S Senkung des serum cholesterols
US6897199B2 (en) * 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
SI1505066T1 (sl) * 2002-04-19 2007-04-30 Faes Farma Sa Polimorf 4-(2-(4-(1-(2-etoksietil)-1h-benzimidazol-2-il) -1-piperidinil)-alfa, alfa-dimetil-benzenocetne kisline
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
DE602004022153D1 (de) 2003-05-14 2009-09-03 High Point Pharmaceuticals Llc Verbindungen zur behandlung von obesitas
MXPA06003474A (es) 2003-09-30 2006-06-05 Novo Nordisk As Agonistas de receptores de melanocortina.
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
PT1723128E (pt) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
JP2007536344A (ja) 2004-05-04 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ 新規のインドール誘導体
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
US8148412B2 (en) 2004-12-03 2012-04-03 Novo Nordisk A/S Heteroaromatic glucokinase activators
EP2386554A1 (en) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
BRPI0612996A2 (pt) 2005-07-14 2010-12-14 Novo Nordisk As ativadores de urÉia glucocinase
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
DK1951658T3 (da) 2005-11-17 2012-10-15 Lilly Co Eli Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser
US8394842B2 (en) 2006-03-28 2013-03-12 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
EP2079732B9 (en) 2006-05-29 2012-03-21 High Point Pharmaceuticals, LLC 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
US8022066B2 (en) 2006-11-15 2011-09-20 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
EP2097388B1 (en) 2006-11-15 2011-09-07 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
AU2008204530B2 (en) 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
EP2552950A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
EP2670368A4 (en) 2011-02-03 2015-04-15 Pharmedica Ltd NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
RU2013145013A (ru) 2011-03-28 2015-05-10 Ново Нордиск А/С Новые аналоги глюкагона
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
JP2020514365A (ja) 2017-03-15 2020-05-21 ノヴォ ノルディスク アー／エス メラノコルチン４受容体に結合可能な二環式化合物
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
IN182496B (pt) * 1996-02-20 1999-04-17 Reddy Research Foundation
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2746099B1 (fr) * 1996-03-13 1998-04-30 Procede ameliore pour la preparation de derives de l'acide 3-(10-phenothiazyl)-propanoique ou 3-(10-phenoxazyl)-propanoique
CN1196730A (zh) * 1996-06-19 1998-10-21 雷迪博士研究基金会 具有增强的抗糖尿病活性的穴糖酮的新的多晶型形式及其制备方法
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
AU1887999A (en) * 1998-01-29 1999-08-16 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2002507543A (ja) * 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物

Also Published As

Publication number Publication date
CA2370401A1 (en) 2000-10-26
RU2001130883A (ru) 2004-03-20
HRP20010748A2 (en) 2003-02-28
TR200103851T2 (tr) 2002-04-22
IL145958A0 (en) 2002-07-25
AU3831300A (en) 2000-11-02
NO20015016D0 (no) 2001-10-15
EE200100529A (et) 2002-12-16
BG106022A (bg) 2002-04-30
CZ20013711A3 (cs) 2002-07-17
CN1351597A (zh) 2002-05-29
NO20015016L (no) 2001-12-11
HUP0200758A3 (en) 2003-07-28
WO2000063192A1 (en) 2000-10-26
HUP0200758A2 (hu) 2002-07-29
MXPA01010472A (es) 2002-05-06
PL351492A1 (en) 2003-04-22
EP1171430A1 (en) 2002-01-16

Similar Documents

Publication Publication Date Title
TR200103851T2 (tr) Bir antidiyabetik maddenin yeni polimorfik formları, bunların hazırlanması için işlem ve bunları farmasötik bileşimler
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BR0214469A (pt) 17alfa-alquil-17beta-óxi-estratrienos e produtos intermediários para sua preparação, aplicação dos 17alfa-alquil-17beta-óxi-estratrienos para a preparação de medicamentos bem como preparações farmacêuticas
BR9915727A (pt) ésteres derivados de compostos de fenil-ciclohexila substituìdos
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BR0013184A (pt) Amidas de ácido carboxìlico, composições farmacêuticas contendo estes compostos, uso e preparação destes
CY1107899T1 (el) 6.αλφα., 9.αλφα. - διφθορο-17.αλφα.-(2-φουρανυλοανθρακοξυλικο) οξυ-11.βητα.-υδροξυ-16.αλφα.-μεθυλο-3-οξο-ανδροστα-1,4-διενιο-17-ανθρακοθειϊκο οξυ s-φθορομεθυλο εστερας ως αντιφλεγμονωδης παραγοντας
BR0116482A (pt) Derivados de difenilazetidinona, processo para a preparação, medicamentos contendo esses compostos e seu emprego.
BR0108893A (pt) Composição farmacêutica, composto e processo de preparação de compostos
BR0113989A (pt) Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos
BR9907866A (pt) Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia
BR0114196A (pt) Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
BR0212069A (pt) Agentes antidiabéticos orais
BR9802804A (pt) Compostos benzimidazol, benzoxazol e benzotiazol, processo para sua preparação e composições farmacéuticas contendo os mesmos.
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
BR9908458A (pt) Tiolésteres de ácido 11beta-benzaldoxim-estra-4,9-dien-carbÈnico substituìdos por s, processos para a sua preparação e preparados farmacêuticos contendo estes compostos
KR900012892A (ko) 항-염증성 아릴 화합물
BR0012478A (pt) Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos
SE9904507D0 (sv) New compounds
CA2143252A1 (fr) Derives de benzodioxane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BRPI9509819B8 (pt) benzamida enterocinética e composição farmacêutica compreendendo a mesma
ATE19236T1 (de) (omega-(diaethylamino)-alkoxy)-alpha-(aethyl)benzhydrolderivate, ihre saeureadditionssalze und quaternaeren salze, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
BR9808722A (pt) Composições farmacêuticas de tizoxanida e nitazoxanida
BR0309014A (pt) ácido(2-((2-alcóxi)-fenil)-ciclopent-1-enil)carbo e heterocìclico aromático e derivados

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A, 6A, E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007.